$ cat ./records/gates-foundation-supports-gavi-oral-cholera-vaccine-emergency-sto-2014.txt
Gates Foundation Supports Gavi Oral Cholera Vaccine Emergency Stockpile for Outbreak Response
[RECORD.TXT] · cat --full
With Gates Foundation support, Gavi established a global emergency stockpile of oral cholera vaccine (OCV) managed by the International Coordinating Group, making doses available within 72 hours of a confirmed outbreak. Prior to the stockpile, OCV was unavailable for outbreak response due to manufacturing constraints. Gates funding helped negotiate a tiered price from EuBiologics and Shanchol producers at approximately $1.60–$1.85 per dose for Gavi-eligible countries, enabling deployment in Yemen, Zimbabwe, and DRC crises.
Source: https://www.gavi.org/types-support/vaccine-support/oral-cholera
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Grants $14.5 Million to The Nature Conservancy for Agricultural Land-Use and Conservation
Next →
Gates Foundation Joins Global Health Security Agenda to Strengthen 70-Nation Outbreak Detection
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.